{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"42.8","value":"14.3"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"26.0","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"OR: CR or PR determined by investigator according to RECIST v1.1 from date of first dose of study treatment until date of first documentation of PD, confirmed by repeat assessments performed no less than 4 weeks after first response. CR: disappearance of target and non-target lesions, with exception of nodal disease and normalization of tumor markers. All nodes, target and non-target must have short axis measures \\<10 mm. PR: \\>=30% decrease in sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference baseline sum of diameters. Non-target lesions must be non-PD. PD: \\>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm, appearance of one or more new lesions was considered PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"During Phase 2 participants with NSCLC received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG000","title":"Combination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 2 participants with SCCHN received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG001","title":"Combination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab"}],"paramType":"NUMBER","populationDescription":"The analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received.","reportingStatus":"POSTED","timeFrame":"From start of the treatment until disease progression or death due to any cause, whichever occurred first (approximately 26 months)","title":"Phase 2: Percentage of Participants With Confirmed OR as Per RECIST v 1.1 by Investigator Assessment for Combination B","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}